CTLA4 and neoplasm: In contrast with the notion of inducing anti-tumour activity, initial anti-CTLA-4 blockade data were ambiguous with evidence that anti-CTLA-4 mAbs enhanced mixed lymphocyte responses but also suppressed effector T cells activated by agonist anti-CD3 and CD28 mAbs [45, 46].